| Gene ID | 1557 |
| Symbol | CYP2C19 |
| Synonymous | CPCJ|CYP2C|CYPIIC17|CYPIIC19|P450C2C|P450IIC19 |
| Full name | cytochrome P450, family 2, subfamily C, polypeptide 19 |
| Gene description | (R)-limonene 6-monooxygenase|(S)-limonene 6-monooxygenase|(S)-limonene 7-monooxygenase|S-mephenytoin 4-hydroxylase|cytochrome P-450 II C|cytochrome P450 2C19|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19|cytochrome P450-11A|cy |
| Cytoband | 10q24 |
| Gene type | protein-coding |
| Synonymous | MIM:124020; HGNC:HGNC:2621; Ensembl:ENSG00000165841; HPRD:00486; Vega:OTTHUMG00000018799 |
Pathways and Diseases | Detail |
|---|---|
Pathway | Xenobiotics;PID Reactome;500197 |
Pathway | Metabolism of xenobiotics by cytochrome P450;KEGG PATHWAY;hsa00980 |
Pathway | Metabolic pathways;KEGG PATHWAY;hsa01100 |
Pathway | Biological oxidations;Reactome;REACT:13433 |
Pathway | Linoleic acid metabolism;KEGG PATHWAY;hsa00591 |
Pathway | Drug metabolism - cytochrome P450;KEGG PATHWAY;hsa00982 |
Pathway | Retinol metabolism;KEGG PATHWAY;hsa00830 |
Pathway | Arachidonic acid metabolism;KEGG PATHWAY;hsa00590 |
Disease | Gastroesophageal Reflux;GAD |
Disease | amitriptyline metabolism;GAD |
Disease | Clopidogrel, impaired responsiveness to;OMIM |
Disease | Acenocoumarol maintenance dosage;NHGRI |
Disease | liver disease;GAD |
Disease | quazepam pharmacokinetics;GAD |
Disease | rabeprazole pharmacokinetics;GAD |
Disease | phenobarbital pharmacokinetics phenytoin pharmacokinetics;GAD |
Disease | omeprazole metabolism;GAD |
Disease | etizolam pharmacokinetics;GAD |
Disease | bladder cancer;GAD |
Disease | esophageal cancer;GAD |
Disease | Acute Coronary Syndrome;GAD |
Disease | Recurrence;GAD |
Disease | H. pylori infection;GAD |
Disease | metabolism disorders;GAD |
Disease | ovarian toxicity, cyclophosphamide-related premature menopause, cyclophosphamide-related;GAD |
Disease | lung cancer;GAD |
Disease | IMMUNE;GAD |
Disease | harm avoidance;GAD |
Disease | depression;GAD |
Disease | carisoprodol metabolism;GAD |
Disease | Acenocoumarol maintenance dosage;GAD |
Disease | PHARMACOGENOMIC;GAD |
Disease | methadone toxicity;GAD |
Disease | sulfone metabolism;GAD |
Disease | INFECTION;GAD |
Disease | anesthesia effects diazepam pharmacokinetics;GAD |
Disease | clopidogrel;GAD |
Disease | METABOLIC;GAD |
Disease | ovarian toxicity;GAD |
Disease | PSYCH;GAD |
Disease | imipramine plasma concentrations;GAD |
Disease | Myelodysplastic Syndromes;GAD |
Disease | chlorpropamide pharmacokinetics;GAD |
Disease | omeprazole pharmacokinetics;GAD |
Disease | clomipramine metabolism;GAD |
Disease | CARDIOVASCULAR;GAD |
Disease | CANCER;GAD |
Disease | lasoprazole pharmacokinetics;GAD |
Disease | Opremazole poor metabolizer;OMIM |
Disease | indisulam pharmacokinetics;GAD |
Disease | epilepsy;GAD |
Disease | Proguanil poor metabolizer;OMIM |
Disease | phenytoin;GAD |
Disease | gliclazide pharmacokinetics;GAD |
Disease | NEUROLOGICAL;GAD |
Disease | Behcet's Disease;GAD |
Disease | gastroesophageal reflux disease;GAD |
Disease | breast cancer;GAD |
Disease | Mephenytoin poor metabolizer;OMIM |
Disease | esophagitis;GAD |
Disease | ulcer, gastric;GAD |
Disease | stomach cancer;GAD |
Sequence Information | |
|---|---|
Nucleotide Sequence | >1557 : length: 1799 GTCTTAACAAGAGGAGAAGGCTTCAATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGGAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGG CCCCACTCCTCTCCCAGTGATTGGAAATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATCTATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGA ACGCATGGTGGTGCTGCATGGATATGAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTCCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAAT CGTTTTCAGCAATGGAAAGAGATGGAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGCATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCT TGTGGAGGAGTTGAGAAAAACCAAGGCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCCATTATTTTCCAGAAACGTTTCGATTATAAAGATCA GCAATTTCTTAACTTGATGGAAAAATTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCCACTATCATTGATTATTTCCCGGGAACCCATAACAA ATTACTTAAAAACCTTGCTTTTATGGAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCTCGGGACTTTATTGATTGCTTCCTGATCAAAATGGA GAAGGAAAAGCAAAACCAACAGTCTGAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAGACAACAAGCACAACCCTGAGATATGCTCTCCTTCT CCTGCTGAAGCACCCAGAGGTCACAGCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAGGACAGGGGCCACATGCCCTACACAGATGCTGTGGT GCACGAGGTCCAGAGATACATCGACCTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTCATTCCCAAGGGCACAACCATATTAACTTCCCTCAC TTCTGTGCTACATGACAACAAAGAATTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAGAAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAA ACGGATTTGTGTGGGAGAGGGCCTGGCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCTCTGATTGACCCAAAGGACCTTGACACAACTCCTGT TGTCAATGGATTTGCTTCTGTCCCGCCCTTCTATCAGCTGTGCTTCATTCCTGTCTGAAGAAGCACAGATGGTCTGGCTGCTCCTGTGCTGTCCCTGCAGCTCTCTTTCCTCTGGTCCAA ATTTCACTATCTGTGATGCTTCTTCTGACCCGTCATCTCACATTTTCCCTTCCCCCAAGATCTAGTGAACATTCAGCCTCCATTAAAAAAGTTTCACTGTGCAAATATATCTGCTATTCC CCATACTCTATAATAGTTACATTGAGTGCCACATAATGCTGATACTTGTCTAATGTTGAGTTATTAACATATTATTATTAAATAGAGAAAGATGATTTGTGTATTATAAAAAAAAAAAA |
Protein Sequence | >1557 : length: 490 MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKIYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRGHMPYTDAVVHEVQRYID LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFKKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP PFYQLCFIPV |